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ABSTRACT
Background: The rates of Type 2 Diabetes (T2D) have increased over the past 20 years in all
age groups. The physiological factors that underlie T2D could have impact on specific brain
pathways that support cognitive and emotional functioning. Aims and Objective: The goal of
this study was to examine whether older Mexican American individuals with a history of T2D
were more likely to develop later cognitive impairment and/or depression. Hypotheses: It was
predicted that elderly participants (mean age at time of interview = 87.87 years) with a history of
T2D onset prior to age 65, are more likely to have dementia-related symptoms and/or symptoms
of depression, as compared to elderly participants with no earlier history of T2D. Specifically,
respondents with T2D were predicted to have greater likelihood of diagnosed dementia (yes/no);
lower (worse) Total Mini-Mental Status Examination scores; and higher depression rating scale
scores. Methods: The hypotheses were tested using respondent data from the Hispanic
Established Populations for the Epidemiologic Study of the Elderly (HEPESE) Wave 8, 20122013 [Arizona, California, Colorado, New Mexico, and Texas] (ICPSR 36578). The original
Wave 8 dataset included 744 respondents; N = 506 had data points needed for the proposed
analyses. The mean age of Wave 8 respondents included for analysis was 87.87 years. The
analyzed sample was 65.6% female; 29.8% had a T2D diagnosis; and 19.8% had a formal
diagnosis of Alzheimer’s or Dementia. Descriptive statistics were calculated for all variables.
Hypotheses involving categorical variables were tested using Chi-Square tests. For continuous
variables, distribution analyses (N, standard deviation, variance, skewness) were examined and
data were analyzed using two-way ANOVAs. Results: Chi-square tests were not significant. The
frequency of dementia diagnoses among respondents with early or any T2D, were not
significantly increased as compared to respondents without early T2D or any T2D. Overall, the
vi

ANOVA results were also not significant but revealed some interesting trends. Regarding
mental function scores, the overall model predicting MMSE scores from T2D, sex, and the
interaction, was statistically significant, but none of the individual factors were significant. When
the direction of effects was examined, it was opposite to the original prediction. Respondents
with T2D had higher rather than lower mental function scores, as compared to those without
T2D. Regarding ratings for reported depression, the overall model was significant, and the tests
of individual factors showed that this was attributable to higher levels of depression symptoms
reported by females as compared to males. Conclusions: Despite using all the available
respondents for these exploratory secondary data analyses, small sub-group sizes limited the
statistical power to detect possible effects. Nonetheless, the findings suggested that a T2D
diagnosis may yield protective effects for the brain, perhaps due to T2D medication effects,
and/or healthier lifestyle and dietary recommendations usually given to those with a T2D
diagnosis. As compared to elderly males, elderly females with earlier T2D reported significantly
more depression than males. While largely not significant, the findings suggested several novel
directions for future research. Studies are needed to determine whether increased mental function
among T2D participants may be attributable to medication use or lifestyle changes. Recent
studies have suggested that Metformin, a common treatment for T2D, is directly and indirectly
anti-inflammatory. Further studies are needed to understand whether the increased MMSE scores
among T2D participants in this study could be attributable to the medications prescribed, and or
lifestyle and dietary changes typically recommended, including increased exercise and reduced
sugar intake. Additional studies are also needed to determine whether female T2D participants
are uniquely vulnerable to depressive symptoms. As life expectancy continues to increase, it
may be important to develop standards that aid in appropriately diagnosing, treating, and
vii

managing symptoms of Type 2 Diabetes (T2D), in an effort to help lower the risk for developing
Alzheimer’s Disease/Dementia in later life. Further research is needed to explore the connection
between these disorders, specifically in Hispanic populations.
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CHAPTER 1: INTRODUCTION
Across the globe, it is estimated that roughly 422 million people are living with diabetes
(WHO, 2020). In the United States alone, more than 34 million Americans have diabetes (about
1 in 10 people), and around 90-95% of those have type 2 diabetes (CDC, 2019). Primarily, there
is a high prevalence of Type 2 Diabetes specifically in Hispanics living in the United States.
According to the National Diabetes Statistics Report, (NDSR, 2020), the prevalence of
diagnosed diabetes in the United States is as follows: American Indians/Alaska Natives (14.7%),
people of Hispanic origin (12.5%), non-Hispanic blacks (11.7%), non-Hispanic Asians (9.2%)
and non-Hispanic whites (7.5%). With Hispanics accounting for 23% of the US population, there
is a definite overburden of Type 2 Diabetes within this demographic (CDC, 2019). Age adjusted
data for 2017-2018 in the NDSR shows that in US adults aged 18 years or older, non-Hispanic
blacks and people of Hispanic origin had a higher incidence of diagnosed diabetes as compared
to non-Hispanic whites.
1.1 PREVALENCE OF DIABETES
The prevalence of diabetes has seen an increasing trend in adults in the United States.
Data collected from the National Health and Nutrition Examination Survey (NHANES) through
the years 1999 – 2016 shows that there was an increase in the estimated prevalence of diabetes in
adults aged 18 years or older in the United States (National Diabetes Statistics Report, 2020).
The National Diabetes Statistics Report (2020) also reported that there are roughly 24.2 million
people aged 65 years or older who have prediabetes. The NHANES data collected in 1999 –
2002 shows that there was about 9.5 percent of adults living with diabetes in the U.S. The
NHANES data from the years 2009 – 2012, also showed time showed that there were roughly
11.3 percent of adults living with diabetes in the U.S. In the decade from 1999 to 2012 alone,
1

NHANES data showed that there was a 1.8 percent increase in the prevalence of diabetes in
adults. When looking at the NHANES data from 2013-2016, there were a total of 12 percent of
adults living with diabetes. This is a 0.7 percent increase from the data collected from 2009 –
2012 and a 2.5 increase from the data collected from 1999 – 2002.
1.2 INCIDENCE OF DEMENTIA
It is well known that the incidence of dementia increases with advancing age. Because
people are living longer life expectancies than previously before, the number of adults with
dementia is expected to increase 3-fold by 2050 (Martin Prince, Renata Bryce, Emiliano
Albanese, Anders Wimo, Wagner Ribeiro, Cleusa P. Ferri, 2013). Although this is the case,
currently the prevalence of dementia has decreased overall in the United States from the year
2000 to 2012 (Langa KM, Larson EB, Crimmins EM, et al., 2017). After analysis of a large
nationally representative survey, Langa KM, Larson EB, Crimmins EM, et al. found that the
prevalence of dementia in adults aged 65 years or older had decreased from 11.6% in 2000 to
8.8% in 2012. While this temporary trend was promising, it is worth noting that as the number of
older Americans continues to increase, the number of existing cases will continue to increase just
as rapidly. According to the Alzheimer’s association, by 2050, there will be a projected 12.7
million people aged 65 years or older with Alzheimer’s dementia alone (2021). Furthermore, the
severity of morbidity should not be overlooked. The Alzheimer’s association states that 1 in 3
seniors dies with Alzheimer’s or other dementias, which is more than breast and prostate cancer
combined (2021). With the rapid increase in life expectancy and the projected increase of
dementia, there is an urgent need for research to help prevent, slow, and/or cure this disease.
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE
2.1 TYPE 2 DIABETES (T2D) AND DEMENTIA AMONG MEXICAN
AMERICANS/HISPANICS IN EL PASO, TX
While not always discussed together, it is perhaps not a coincidence that Type 2 diabetes
(T2D) and dementia have become common in a growing proportion of the population, especially
among older Mexican American individuals living in the El Paso Border Region where the
population is 82.9% Hispanic (Census,2018). As will be discussed in detail below, T2D and
dementia share some key physiological mechanisms. According to the 2018 U.S. Census, of a
total population of 840,758 people, about 15% of adults aged 18 years and older in El Paso,
Texas had diabetes. In 2017, the Centers for Medicare and Medicaid Services also reported that
about 32.7% of the Medicare beneficiaries in El Paso, Texas were treated for diabetes. Compared
to the national U.S. average of 27.2% and the Texas value of 29.1%, it is clear to see that more
needs to be done to reduce the prevalence of diabetes among Medicare recipients in El Paso,
Texas. It is important to note that about 27.7% of the population aged 65 years and older
reported being told they have diabetes by a health professional (CDC, Behavioral Risk Factor
Surveillance System, 2017). The Centers for Medicare and Medicaid services also reported that
about 12.7% of Medicare beneficiaries were treated for Alzheimer’s disease or dementia in El
Paso, Texas (2018).
2.2 PHYSIOLOGY OF T2D AND COGNITIVE DECLINE
Some research has begun to suggest that T2D may actually predispose some participants
to cognitive decline. As many have pointed out, this possible association is biologically
plausible.
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Type 2 diabetes is a chronic disease in which cells do not respond to insulin, a hormone
produced by the pancreas. This is otherwise known as insulin resistance (CDC, 2019). Insulin
resistance causes there to be too much glucose in the blood rather than in the appropriate cells
(NIDDK, 2016). Uncontrolled levels of blood glucose can lead to serious complications such as
heart disease, stroke, vision loss, dental disease, and nerve damage (NIDDK, 2016). The World
Health Organization attributes diabetes as a “major cause of blindness, kidney failure, heart
attacks, stroke and lower limb amputation” (2020). Not only is Type 2 diabetes costly on its own,
but there are also furthermore physical and mental repercussions that are the consequence of
unmanaged diabetes such as dementia.
2.3 THE EFFECTS OF INSULIN RESISTANCE AND HYPERINSULINEMIA ON
BRAIN FUNCTION
Although type 2 diabetes mellitus can develop at any age, it is most often developed in
people who are over the age of 45 (CDC, 2019). This is a serious concern as it increases the risk
of mortality, reduced functional status and institutionalization in older adults, typically over the
age of 65 (Kirkman et al., 2012). Both aging and diabetes are known to be risk factors for
functional impairment but more importantly, for cognitive dysfunction (Kirkman et al., 2012).
This is primarily due to the presence of insulin resistance and hyperinsulinemia. Insulin
resistance and hyperinsulinemia, both of which are associated with type 2 diabetes, are major
risk factors for dementia, regardless of cerebrovascular disease (Felice, Lourenco, & Ferreira,
2014).
According to Banks et al. (1997), insulin is a peptide that is secreted by pancreatic beta
cells. They are then transported into the central nervous system (CNS) across the blood brain
barrier through a receptor mediated process. These insulin receptors are abundantly found in
4

astrocyte and neuron synapses which are then moved into different portions of the brain.
Specifically, they are transported to the olfactory bulb, cerebral cortex, hippocampus,
hypothalamus, amygdala, and septum (Cholerton, B., Baker, L. D., & Craft, S., 2013).
Insulin is known to influence cognition and memory through the induction of “long term
potentiation,” which is one of the cellular bases for memory function and formation. High levels
of circulating insulin have adverse effects on memory and cognitive function. According to
Cholerton, Baker and Craft, “prolonged peripheral hyperinsulinemia down-regulates insulin
receptors at the blood-brain barrier and reduces insulin transport into the brain” (2013). This
action then results in high levels of insulin which can substantially damage muscle, liver,
adipose, endothelium, and brain tissue, because overtime, these tissues become unresponsive to
insulin. In normal function, the pancreas can physiologically compensate by generating the
needed amount of insulin to help maintain glucose at appropriate levels. Because of this process,
the development of cognitive disfunction and memory loss is attributable to years and decades of
abnormally high levels of insulin (Xu et al., 2009).
Studies indicated that there was a positive correlation between diabetes and cognitive
impairment, indicating that those with diabetes mellitus are at a higher risk of developing
dementia or Alzheimer’s disease. A prospective analysis of 5,099 participants from the
Atherosclerosis Risk in Communities (ARIC) study conducted in 2011-2013 discovered that
diabetes status such as poor glycemic control and diabetes duration was associated with worse
cognitive health outcomes (Rawlings et al., 2019). Specifically, the study identified that midlife
onset of diabetes was a strong risk factor for dementia as compared to late-life onset. In a
separate analysis of the ARIC study, glucose peaks in participants with diabetes were also
identified as a risk factor for cognitive decline and dementia (Rawlings et al., 2017). A meta5

analysis carried out by Chatterjee et al. looked at possible differences between women and men
with type 2 diabetes and the risk for dementia (2016). Although individuals with type 2 diabetes
were at a 60% greater risk for developing dementia, the risk for vascular dementia was 120%
higher in women with type 2 diabetes.
For many reasons, there is a great need for research that further explores the connection
between these disorders. As life expectancy continues to increase, it will be important to develop
standards that aid in appropriately diagnosing, treating, and managing symptoms of T2D, in an
effort to help lower the risk for developing dementia in later life. For example, it is important to
examine whether socio-demographic or health metrics (e.g., bmi, blood pressure, blood glucose,
etc.) predispose older adults with T2D to dementia. it is also important to determine whether
particular signs and symptoms of type 2 diabetes may increase the potential of developing
dementia, specifically among older individuals with T2D.
2.4 T2D AND DEMENTIA U.S.-MEXICO BORDER HEALTH
As stated above, 32.7% of the Medicare beneficiaries were treated for diabetes and 12.7%
of Medicare beneficiaries were treated for Alzheimer’s disease or dementia in El Paso, Texas.
The data currently available however reports the incidences for these diseases separately. It is
critical to determine the extent to which T2D might be predictive of dementias in this the border
region population and more importantly, whether certain demographic or clinical characteristics
distinguish those participants who go on to develop dementia following an earlier diagnosis of
T2D. If such characteristics can be identified, this could define a subgroup of T2D participants
for interventions specifically educate the participants on their higher risk of dementia. It is also
possible that understanding their increased risk of later-life dementia could provide increased
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motivation for T2D participants to make life-style changes aimed at resolving T2D before it
progresses to a more severe form of the disease.
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CHAPTER 3: RESEARCH PURPOSE
There central aim of this research is to determine whether older Mexican American
individuals with a history of type 2 diabetes (T2D) who later developed cognitive decline, differ
in quantitatively identifiable ways as compared to those with earlier T2D who did not go on to
experience subsequent cognitive decline. Different variables will be examined for all participants
and compared across participants who did and did not develop T2D. The variables will include
T2D diagnosis(yes/no), age when diagnosed with T2D (pre-age 65, post-age 65, Never
diagnosed), diagnosed Alzheimer’s Disease/Dementia, cognitive ability (Total MMSE Score),
emotional functioning (CES-D score). Additionally, differences in gender (male/female) will
also be examined to determine if there are significant differences between the two that might
have any identifiable influence on these outcomes.

8

CHAPTER 4: STUDY AIM AND HYPOTHESES
4.1 SPECIFIC AIM
Aim 1: The aim of this study was to examine whether older Mexican American individuals with
a history of T2D were more likely to develop later cognitive impairment and/or depression.
4.2 HYPOTHESIS
It is hypothesized that elderly participants (mean age at time of interview = 87.87 years) with a
history of T2D onset prior to age 65, are more likely to have dementia-related symptoms and/or
symptoms of depression, as compared to elderly participants with no earlier history of T2D.
Specifically, respondents with T2D were predicted to have greater likelihood of diagnosed
dementia (yes/no); lower (worse) Total Mini-Mental Status Examination scores; and higher
depression rating scale scores.

9

CHAPTER 5: MPH PROGRAM FOUNDATIONAL COMPETENCIES
The following foundational competencies were applied throughout this research:
A. Evidence-based Approaches to Public Health
1. Apply epidemiological methods to the breadth of settings and situations in public health
practice.
5. Analyze quantitative and qualitative data using biostatistics, informatics, computer-based
programming, and software, as appropriate.
6. Interpret results of data analysis for public health research, policy, or practice.
C. Planning & Management to Promote Health
7. Assess population needs, assets and capacities that affect communities’ health.
D. Policy in Public Health
13. Propose strategies to identify stakeholders and build coalitions and partnerships for
influencing public health outcomes.
14. Advocate for political, social, or economic policies and programs that will improve health
in diverse populations.
E. Leadership
F. Communication
18. Select communication strategies for different audiences and sectors.
19. Communicate audience-appropriate public health content, both in writing and through
oral presentation.
H. Systems Thinking

10

CHAPTER 6: METHODS
6.1 SECONDARY DATA ANALYSIS
For this study, secondary data will be used to examine whether a participants T2D
diagnosis, may distinguish those older adults who went on to develop dementia. The data to be
analyzed in this study weas taken from the series of studies entitled “Hispanic Established
Populations for the Epidemiologic Studies of the Elderly (Hispanic EPESE)”. HEPESE Wave 8,
the specific series used in these analyses, is a part of the Hispanic EPESE longitudinal study
series. This longitudinal study carried out its first wave from 1993 to 1994. The HEPESE Wave
8 was the last set of data from the series which collected its’ data from 2012-2013. The data
collected from this series of studies was modeled after the design of the Established Populations
For Epidemiologic Studies Of The Elderly, 1981-1993: [East Boston, Massachusetts, Iowa And
Washington Counties, Iowa, New Haven, Connecticut, And North Central North Carolina] (Icpsr
9915) and Established Populations For Epidemiologic Studies Of The Elderly, 1996-1997:
Piedmont Health Survey Of The Elderly, Fourth In-Person Survey [Durham, Warren, Vance,
Granville, And Franklin Counties, North Carolina] (Icpsr 2744).
The dataset was established by utilizing the Inter-university Consortium for Political and
Social Research (ICPSR) database. To select and appropriate study to analyze, a general text
search for “diabetes dementia” in the “Search Data and Site” toolbar was made. A total of 206
search results were displayed and then filtered for applicability to the research question. The
dataset had to include Hispanic respondents over 65 years of age, be a longitudinal study and
must include data on diagnosed diabetes and dementia. The data set was then selected and
inspected for suitable variables that could be applied to the research question.
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In the sample, n=479 participants were female, and n=265 participants were male, for a
total of n=744 participants. the age range of participants at the last survey timepoint was 82 to
103 years of age. The total number of respondents who self-reported a diabetes diagnosis
consisted of n=248 people in the sample, including 166 females and 82 males. The total number
of participants who had Alzheimer’s Disease/Dementia was n=213, which includes 137 females
and 76 males.
6.2 ACCESS TO DATA
This dataset was available for public access through the National Archive of
Computerized Data on Aging (NACDA). In order to gain access to the complete dataset, one
must agree to the terms of use listed by NACDA. Once a user agrees to the terms of use, a
MyData count must be created. This will allow the user download data, use online analysis tools,
generate reports, and download statistics. The download will then begin once sign up or sign in
has been completed. A codebook, which detailed the study, was available by gaining access to
the original dataset when the study was first carried out from 1993-1994. No further requests
were needed for access to this publicly available dataset.
6.3 DATA PLAN
Variables were reviewed from the dataset for applicability to the research question. There
was a total of 313 variables included in the dataset. Some of the variables were additionally
created by the original researchers to help calculate total scores for specific sections of the
questionnaire which was required for complete analysis. The variables that were primarily
selected were related to both diabetes and dementia.

12

6.3.1 DIABETES
For diabetes, the following variables the following were selected for analysis:
1. Factor: Diagnosed Diabetes
Variable name in database: MDIAB81
Determined by: Self-report (“Have you ever been told by a doctor that you have
diabetes…”)
Scale: Nominal/Dichotomous – 1=”Yes, 2=”No”
2. Factor: Diagnosed Diabetes Age
Variable name in database: MDIAB82
Determined by: Self-report (“At what age did a doctor first tell you that you have
diabetes?”)
Scale: Continuous/Numeric – Measured in years to 2 decimal places

When looking at diabetes, the main variable utilized for this analysis is diagnosed
diabetes (MDIAB81) (yes/no). This variable will be used to analyze any differences in those who
have diabetes versus those who do not have diabetes. Of 744 valid responses, 248 responded that
they have been told by a doctor that they have diabetes. Another factor that will be observed for
diabetes is age when diagnosed with diabetes. This will allow for analysis on whether age when
diagnosed with diabetes changes the risk for developing dementia. 200 respondents provided an
age of when they were diagnosed with diabetes. Ages will be grouped into three groups; 1) T2D
pre-age 65, 2) T2D post-age 65, and 3) No T2D. This was established to better visualize age
when diagnosed with T2D and to aid in analyses.

13

6.3.2 DEMENTIA
For the variable dementia, the following were selected for analysis:
1. Factor: Cognitive Ability (Total MMSE Score)
Variable name in database: TOTMMSE8 (Testing done on the same day current
age was recorded)
Determined by: Cognitive test/Mini-Mental Status examination
Scale: Total score on test (Range (0-30), Mean 19.9, Std. 7.8 (n=665)
2. Factor: Diagnosed Dementia
Variable name in database: U83U
Determined by: Self-report (“Have you ever been told by a doctor that you have
Alzheimer’s Disease/Dementia?”)
Scale: Nominal– 1=”Yes, 2=”No”, 8=”Don’t know”

For Dementia, one of the variables for this analysis is total Mini Mental State
Examination (MMSE) Score (TOTMMSE8), which is used to determine cognitive ability of the
participant. This variable will be used to analyze any differences in those who have poor
cognitive scores versus those who do not have poor cognitive scores on the MMSE. The variable
was recoded to create a new variable “Dementia Status” that differentiated the score of each
participant to indicate dementia status. Of 744 valid responses, 97 participants scores indicated
“Normal Cognition” (25-30 points), 165 participant scores indicated “Mild Dementia” (24-21
points), 213 participant scores indicated “Moderate Dementia” (20-10 points), and 97
participants sored indicated “Severe Dementia” (9-0 points). For the variable diagnosed dementia
(U83U), out of 744 valid responses, 213 participants reported being told by a doctor that they
14

have Alzheimer's Disease/Dementia, while 522 participants responded that they have never been
told by a doctor that they have Alzheimer's Disease/Dementia.
6.3.3 OTHER VARIABLES
The following have been identified as supporting variables for the purposes of this
analysis which includes variables not limited to diabetes and dementia:
1. Factor: Chronological Age
Variable name in database: AGE8
Determined by: Self-report
Scale: Continuous/Numeric - Measured in years to 3 decimal places
2. Factor: Sex/Gender
Variable name in database: SEX8
Determined by: Self-report
Scale: Nominal/Dichotomous – 1=”Male”, 2=”Female”
3. Factor: History of brain stroke/hemorrhage
Variable name in database: JSTROK81
Determined by: Self-report
Scale: Nominal – 1=”Yes”, 2=”No”, 8= Don’t know”
Scale: Ordinal – (0) Rarely/None, (1) Some/Little, (2)
Occasionally/Moderate, (3) Most/All

15

6.4 SAMPLE UNIVERSE
The geographical area of interest in this longitudinal study was the 5 southern states on
the United States-Mexico border. These include Arizona, California, Colorado, New Mexico,
and Texas. The purpose of the Hispanic EPESE series was to determine the prevalence of
physical, mental, and functional impairments in older Mexican Americans 65 years or older. The
intent of the study was to compare the estimates to other populations to determine the occurrence
of these conditions in older Mexican American populations. In particular, the researchers’
purpose was to identify if certain risk factors for mortality and morbidity operate differently in
Mexican Americans than in non-Hispanic White Americans, African Americans, and other major
ethnic groups. To do so, they collected demographic characteristics (age, sex, type of Hispanic
race, income, education, marital status, number of children, employment, and religion), height,
weight, social and physical functioning, chronic conditions, related health problems, and health
habits. As well, self-reported use of dental, hospital, and nursing home services, along with selfreported depression was also collected.
6.5 QUALITY OF DATA
The data collected for the purposes of the Hispanic EPESE were completed using survey
questionnaires. Harris Interactive Inc., a contract agency, was responsible for hiring and training
interviewers to do the majority of the field work such as, completing interviews, and obtain
physical measurements of participants. Interviews were carried out in the preferred language of
the respondents: English or Spanish. The data consisted of a combination of clinical and survey
data. Primarily, interviews were conducted in person at the respondent’s residence. During these
interview sessions, questionnaires and physical assessments were conducted at each visit.
Physical assessments included the collection of:
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•

Blood pressure measurement at baseline and at first follow up interview

•

Performance-based assessments of physical functioning

•

Height and weight measures

•

Waist and hip measures

•

Vision assessment

•

Medication use

The HEPESE 8th wave (2012-2013), was the eighth and final visit in this longitudinal study.
Because of the nature of this study, these interviews were repeated over the course of eight times.
A mini mental exam was also given to assess the mental capabilities of each respondent. As well,
CES-D, a depression screen, was utilized to help collect data regarding respondent’s mental
health status regarding depression. Activities of Daily Living (ADLs) and Instrumental Activities
of Daily Living (IADLs) was also assessed in addition to the general demographics collected.

The content of the survey (Appendix 1) itself is broken down to collect data through the
utilization of the following categories:
A. Demographic characteristics
1a. Age
2a. Marital Status
3a. Education
4a. Annual Income
5a. Work and Retirement Status
6a. Occupation
7a. Language of Interview
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8a. Immigrant Status
B. Social functioning
1b. Household Composition (Living Arrangements)
2b. Number of Children
3b. Religion
4b. Non-religious Group Membership
5b. People One (Self) Can Count On
C. Physical functioning
1c. Activities of Daily Living (ADL) - basic mobility and neurological activities
required for community living.
2c. Instrumental Activities of Daily Living - identifies elderly individuals who are
having difficulty performing important activities of living and as such may be at
risk for loss of independence in a community setting.
3c. Performance-Based Measures – measures objectively used to evaluate mobility,
strength, gait, and balance, and may predict transitions from a non-disabled state
to a disabled state in older persons.
4c. Sensory Impairment - vision and hearing impairments that can adversely
influence daily functioning and are associated with ADL disability and
performance-based functional decline.
D. Chronic conditions
1d. Diabetes
2d. Hypertension
3d. Cancer
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4d. Hip and Bone Fractures
5d. Heart Attack
6d. Stroke
7d. Arthritis
8d. Gallbladder Disease
9d. Multiple Medical Conditions (Comorbid Chronic Conditions)
E. Related health problems
1e. Height and Weight
2e. Control of Urination
3e. Depressive Symptoms
4e. Mental Status - Mini-Mental State Examination (MMSE) used to assess
cognitive function.
5e. Sleep Problems
F. Health habits
1f. Cigarette Smoking
2f. Alcohol Use
G. Self-reported health services utilization
1g. Type of Insurance
2g. Hospitalization
3g. Dental Services
H. Chronic and acute stressors
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1h. Life Events - death of someone close, personal illness or injury, illness of close
relative or friend, and worsening financial situation, having been the victim of
crime, becoming a caregiver, and having a spouse hospitalized.
2h. Chronic Economic strains - not having enough money to afford food, medical
care, or bills.
6.6 SAMPLING STRATEGY UTILIZED IN HEPESE STUDY
The initial baseline sample was determined in the summer of 1993. The first of the initial
interviews began in August of 1993 and were completed by June 1994. Harris Interactive,
Incorporated. Dr. Marty Frankel, statistical consultant for Harris Interactive, developed the
sampling design. Specifically, by listing counites of the Southwestern states by rank by the
number of older Mexican Americans, the area probability sample design to be used was
developed.
The sample population in this series was selected through the use of multistage, stratified
and probability sampling. Firstly, universe counties were ranked in each state from Census
Bureau figures on the basis of the greatest number of Mexican American elderly, 65 years or
older, residing in the area. To help determine this, a cut off number was established where
counties with ninety percent of the Mexican Americans were included in the study universe.
They also included any county below the cutoff with more than 60 percent of the population
being Mexican American elderly. The study then selected three hundred census tracts from 1990
that met inclusion criteria and were the primary sampling units (PSU’s). A list was then
compiled to determine a cumulative total of households in each tract, which amounted to a
minimum of four hundred households per unit. Listings were then developed for each housing
unit and mapped for interviewing purposes.
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Interviewers were able to identify and screen 175 households per sampling unit and was
completed in two phases. Ultimately, the total number of eligible respondents from the selected
30,000 households helped to determine the size needed for phase two. Interviewers identified
interview eligible respondents for phase one and were able to contact the first 100 housing units,
then in a second phase, an additional 75 contacts (households) were made. To complete
interviews, up to four attempts were made to contact each household. Letters were left behind at
households where no one was home to inform them of their visit. When a respondent was
identified, up to four additional attempts were made to complete the full interview but allowed
up to a fifth visit in instances that met exemptions. If an interview was attempted but a household
member refused, a separate interviewer may visit again the next day to attempt to gain another
household for interviewing purposes.
A total of 3,050 home interviews were conducted with subjects who were Mexican or
Mexican American origin. They were identified as applicable interviewees through the use of the
U.S. Census procedures and the Hazuda algorithm for identifying Mexican Americans. For this
specific EPESE, the 83% response rate is said to be better than that of other EPESE surveys
which required adjustments for design effects due to the complex sample design. Trained
interviewers interviewed and examined subjects in the respondents’ own homes. All interviewers
were specifically trained by a third party, Harris Interactive, but were also trained through
medical personnel, and by Hispanic EPESE investigators. Training was provided for blood
pressure measurement, performance-based assessments of physical functioning, height and
weight, waist and hip, vision assessment, medication use, and other measures.
Sample weighting was post-stratified for Mexican Americans 65 years and over at the
state level. The first step of sample weighting was to utilize weights that were “inversely
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proportional to the probability of selection at the household level within the tract.” The initial
weight (SW1i) was created using the following parameters:
HHi = total households in the P.S.U. (from census data)
MA65i = total Mexican Americans in the P.S.U. (from census data)
SCHH1 = number of screened households in the P.S.U. (from Harris Interactive)
Ki = 3050 (the sample size) / 5794.726 (SW1ij)
The formula for the initial weight (SW1i) was
𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺
𝑯𝑯𝑯𝑯𝑯𝑯
𝒙𝒙
𝒙𝒙 𝑲𝑲𝑲𝑲
𝟏𝟏𝟏𝟏𝟏𝟏
𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴𝑴

The summation of the initial weight for all subjects in all PSU’s (SW1ij) equaled 5794.726. The
constant (K) was then solved with the equation:
K=

𝟑𝟑𝟑𝟑𝟑𝟑𝟑𝟑 (𝐭𝐭𝐭𝐭𝐭𝐭 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬 𝐬𝐬𝐬𝐬𝐬𝐬𝐬𝐬)
𝟓𝟓𝟓𝟓𝟓𝟓𝟓𝟓.𝟕𝟕𝟕𝟕𝟕𝟕 (𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺𝑺)

K = .52701

Using the above information, the first stage weights (W1) were calculated.
The formula for (W1) was K multiplied by the initial weights (SW1i) : W1=SW1i x K.
Descriptive statistics and crosstabulations by gender and state were created from the first
stage weights (W1) in SAS. Ultimately, the ratio for each state and gender (census/sample) was
computed and multiplied by sample size, then divided by the census size. In total, ten ratios (L)
were applied to each state and gender separately. Furthermore, to calculate final weights (FW),
or post-stratification, the first stage weights (W1) were multiplied by the ten ratios (L) using the
following formula: FW=Wi x L. This process helps to ensure the weighted sample proportional
distribution is equal to the states. As well, inflation rates were calculated to be able to
appropriately compare the sample results to the sample of the Southwest. To obtain these
weights, stage weight (W1) was multiplied by the census total 498,176 and by the ten ratios (L),
then divided the total sample size (3,050). The equation was as follows: IW = (W1*498,176*L)/
3050.
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6.7 STATISTICAL ANALYSES
Because this data is publicly available for download, this study will make use of
statistical software package to develop descriptive analysis of the HEPESE Wave 8 dataset.
IBM® SPSS® Statistics software will be used as a general tool to quickly analyze the variables,
create cross tabulations, create new variables, and generate counts. Once completed, SPSS will
be used to carry out the main statistical analysis and for the purposes of statistical modeling in
order
The hypotheses were tested using respondent data from the Hispanic Established
Populations for the Epidemiologic Study of the Elderly (HEPESE) Wave 8, 2012-2013 [Arizona,
California, Colorado, New Mexico, and Texas] (ICPSR 36578). The original Wave 8 dataset
included 744 respondents; N = 506 had data points needed for the proposed analyses. These were
determined by filtering out to only include those with valid MMSE scores, CES-D scores, and
those that answered whether they had a T2D diagnosis (yes or no), and an Alzheimer’s
disease/Dementia diagnosis (yes or no). The mean age of Wave 8 respondents included for
analysis was 87.87 years. The analyzed sample was 65.6% female; 29.8% had a T2D diagnosis;
and 19.8% had a formal diagnosis of Alzheimer’s or Dementia. Descriptive statistics were
calculated for all variables. Hypotheses involving categorical variables were tested using ChiSquare tests. For continuous variables, distribution analyses (N, standard deviation, variance,
skewness) were examined and data were analyzed using two-way ANOVAs.
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CHAPTER 7: RESULTS
The physiological effects of T2D as reviewed in the Introduction might be expected to
impact brain functions over time. Using pre-existing data from HEPESE, Wave 8, this study
examined whether early diagnosis of T2D (before an age of 65) predicted increased risk of later
diagnosed dementia, cognitive decline, and/or depressive symptomatology. Tests were also run
examining whether diagnosis of T2D at any age predicted increased risk of diagnosed dementia,
cognitive decline, and/or depressive symptomatology. For these exploratory secondary data
analyses, all subjects meeting study criteria were used. The dataset included 174 males and 332
females (N = 506) determined to have no history of stroke and/or brain hemorrhage. (N = 29
subjects were excluded from the original dataset of N = 535 due to past reported history of
stroke/hemorrhage.)
7.1 DESCRIPTIVE ANALYSIS
Descriptive analyses were performed to understand the characteristics of the sample, and
thus to whom the results might apply. Table 1 shows the frequency/counts for respondents by
sex, T2D diagnosis status, and Alzheimer’s/Dementia diagnosis status. For the purposes of this
analysis, participants were split into 3 groups based on respondents’ ages when diagnosed with
T2D. These included No T2D diagnosis; T2D before age 65; and T2D after age 65. Out of 506
cases, 355 (70.2%) of participants did not have a T2D diagnosis; 46 (9.1%) were diagnosed with
T2D before age 65, and 105 (20.8%) were diagnosed with T2D after age 65. Thus, as shown in
Table 1 below, approximately 30% had a formal diagnosis of T2D at some point in their lives,
and approximately 20% of the sample had a formal diagnosis of Alzheimer’s/Dementia. The
sample included more females (65.6%) than males (34.5%).

24

Table 1. Frequency table for categorial variables
Frequenc
y
Sex
Male
174
Female
332
T2D Diagnosis No T2D
355

Percent
34.4
65.6

Valid
Percent
34.4
65.6

Cumulative
Percent
34.4
100.0

70.2

70.2

70.2

T2D < age 65

46

9.1

9.1

79.2

T2D > age 65

105

20.8

20.8

100.0

105

20.8

20.8

20.8

401

79.2

79.2

100.0

Alzheimer’s/Deme Yes
ntia Diagnosis
No

Table 2 below shows the frequencies and counts for all continuous variables. The group sample
sizes were sufficient to proceed with the analyses. To determine if the continuous variables met
assumptions for planned parametric analyses (ANOVA), skewness and kurtosis were considered.

Table 2. Descriptive statistics for continuous variables
N

Valid
Missing

Interview Age
506
0

T2D Age Dx
151
355

Total MMSE
506
0

Total CESD

Mean

87.87

67.72

20.99

12.35

Median
Mode
Range

87.00
87
21

70.00
70
71

21.00
30
28

10.00
8
49

Minimum
Maximum

82
103

20
91

2
30

2
51

506
0

Table 3 and Figures 1 and 2 show the distributions for each of the continuous variables used in
the analyses. Of 506 participants, the youngest participant at the time of interview for Wave 8 of
this study, was 82 years old while the oldest was 103 years old. The distribution shows that the
range of ages tended to lay between 80 - 90 years of age (Figure 1). The ages at which T2D was
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diagnosed ranged from 20 to 91 years old and tended to be around 60 – 80 years of age (Figure
2).
Table 3. Distributions of continuous variables
Min Ma Mea
Std.
Varian
N
.
x.
n Deviation
ce

Interview Age 50
6
T2D Dx Age 15
1
Total CESD 50
6
Total MMSE 50
6
Valid N (listwse) 15
1

82 103 87.8
7
20 91 67.7
2
2 30 20.9
9
2 51 12.3
5

3.517

Skewness
Kurtosis
Statist Std. Statist Std.
ic
Error
ic
Error
.946
.109 .778
.217
506

14.865

-1.107

.197 1.108

.392

151

6.190

-.443

.109 -.282

.217

506

8.289

1.190

.109 1.668

.217

506
151

Mean = 87.87
Std. Dev = 3.517
N=506

Figure 1. Distribution for Age at Time of Interview
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Mean = 67.72
Std. Dev = 14.865
N=151

Figure 2. Distribution for Age at Time of T2D Diagnosis
7.2 INFERENTIAL STATISTICS
For all inferential tests, a significance level of p<0.05 was used. The general hypothesis
predicted that elderly respondents with a history of T2D diagnosis prior to age 65, had a higher
incidence of diagnosed dementia; and/or poorer cognitive functioning (MMSE score); and/or
more depressive symptoms (CESD-20 score) as compared to elderly respondents with no earlier
history of T2D.
7.3 CHI-SQUARE ANALYSES
Four chi-square analyses were conducted. The analysis examined whether participants
with an earlier history of T2D (before age 65) were more likely to be diagnosed with dementia
(yes/no). The cross-tabulations are shown in Table 4 and the Chi-Square results are shown in
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Table 5. There was no significant association between history of T2D diagnosis before age 65
and developing Alzheimer’s disease/Dementia (p = 0.705). Thus, as compared to participants
with no history of T2D, participants with earlier history of T2D were not more likely to have
been diagnosed with dementia (yes/no). Alzheimer’s/Dementia status appeared to be
independent from T2D diagnosis. Participants 65 years of age and older with a history of T2D
onset prior to age 65, do not have a higher incidence of Alzheimer’s/Dementia as compared to
elderly participants with no history of T2D.

Table 4. Cross-tabulation of Alzheimer’s Diagnosis by T2D Diagnosis, Pre-65 vs. No T2D
Diagnosed
Alzheimer's
Disease/Dementia
Yes
No
Total
T2D Diagnosis
No T2D
Count
76a
279a 355
Age
Expected Count
77.0
278.0 355.0
T2D Pre-Age 65 Count
11a
35a
46
Expected Count
10.0
36.0 46.0
Total
Count
87
314 401
Expected Count
87.0
314.0 401.0
Each subscript letter denotes a subset of Diagnosed Alzheimer's Disease/Dementia
categories whose column proportions do not differ significantly from each other at the .05
level.
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Table 5. Chi-Square – Alzheimer’s Diagnosis by T2D Diagnosis, Pre-65 vs N

Value
.150a
.039
.147

df
1
1
1

Asymptotic
Significance Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
.698
.843
.701
.705
.411

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
.150
1
.699
Association
N of Valid Cases
401
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 9.98.
b. Computed only for a 2x2 table

Since the initial chi-square test was not significant, a second chi-square was calculated to
test whether respondents with T2D at any age were more likely to have a diagnosis of
Alzheimer’s/dementia. The cross-tabulations are shown in Table 6 and the Chi-Square results are
shown in Table 7. There was no significant association (p = 0.633) seen between history of T2D
(yes/no) diagnosis and developing Alzheimer’s disease/Dementia. As compared to participants
with no T2D diagnosis, participants with a T2D diagnosis were not more likely to have been
diagnosed with dementia (yes/no). Alzheimer’s/Dementia status appeared to be independent
from T2D diagnosis. Participants with a history of T2D diagnosis at any age, do not have a
higher incidence of Alzheimer’s/Dementia as compared to participants with no history of T2D.
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Table 6. Cross-tabulation of Alzheimer’s Diagnosis by T2D Diagnosis (yes/no)
Diagnosed
Alzheimer's
Disease/Dementia
Yes
No
Total
T2D Diagnosis
Yes
Count
29a
122a 151
Expected Count
31.3
119.7 151.0
No
Count
76a
279a 355
Expected Count
73.7
281.3 355.0
Total
Count
87
105 401
Expected Count
87.0
105.0 401.0
Each subscript letter denotes a subset of Diagnosed Alzheimer's Disease/Dementia
categories whose column proportions do not differ significantly from each other at the .05
level.
Table 7. Chi-Square – Alzheimer’s Diagnosis by T2D Diagnosis (yes/no)

Value
.313a
.193
.316

df
1
1
1

Asymptotic
Significance Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
.576
.660
.574
.633
.333
.576

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
.312
1
Association
N of Valid Cases
506
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 31.33
b. Computed only for a 2x2 table

Another chi-square was run to test whether, within the group of participants with a T2D
diagnosis, age of diagnosis – that is, pre-age 65 vs. post-age 65 – was associated with
Alzheimer’s disease/Dementia. The cross-tabulations for this analysis are shown in Table 8 and
the Chi-Square results are shown in Table 9. There was no significant association was observed
between T2D participants with earlier versus later diagnoses diagnosis and developing
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Alzheimer’s disease/Dementia (p = 0.372). Thus, as compared to participants with pre-65 T2D
diagnosis, participants with post-age 65 T2D were not more likely to have been diagnosed with
dementia (yes/no). Alzheimer’s/Dementia status was not influenced by age of T2D diagnosis.
Table 8. Cross-tabulation of Alzheimer’s Diagnosis by Diagnosed T2D, Pre- vs Post-Age 65
Diagnosed
Alzheimer's
Disease/Dementia
Yes
No
Total
T2D Diagnosis
T2D Pre-age 65
Count
11a
35a
46
Expected Count
8.8
37.2 46.0
T2D Post-age 65 Count
18a
87a 105
Expected Count
20.2
84.8 105.0
Total
Count
29
122 151
Expected Count
29.0
122.0 151.0
Each subscript letter denotes a subset of Diagnosed Alzheimer's Disease/Dementia
categories whose column proportions do not differ significantly from each other at the .05
level.
Table 9. Chi-Square – Alzheimer’s Diagnosis by Diagnosed T2D, Pre- vs Post-Age 65

Value
.945a
.559
.917

df
1
1
1

Asymptotic
Significance Exact Sig. (2- Exact Sig. (1(2-sided)
sided)
sided)
.331
.455
.338
.372
.225
.333

Pearson Chi-Square
Continuity Correctionb
Likelihood Ratio
Fisher's Exact Test
Linear-by-Linear
.939
1
Association
N of Valid Cases
151
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 31.33
b. Computed only for a 2x2 table
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Prior to the analyses, respondents with a history of stroke/hemorrhage were excluded
from the analyses. However, an exploratory analysis with these subjects (n=29) was run to test
whether early T2D (pre-age 65) might have pre-disposed the brain to later stroke/hemorrhage.
Specifically, the chi-square tested whether participants with an earlier history of T2D (pre-age
65) were more likely to experience stroke/brain hemorrhage (yes/no) as compared to those with
no history of T2D. As shown in the cross-tabulation (Table 10), the one cell size was below the
acceptable limit for a valid chi-square (N < 5) and the chi-square analysis was not conducted.

Table 10. Cross-tabulation of History of Stroke or Brain Hemorrhage Diagnosis by Diagnosed
T2D, Pre-Age 65 vs No T2D
History of Stroke or
Brain Hemorrhage
Yes
No
Total
T2D Diagnosis
No T2D
Count
23a
332a 355
Expected Count
23.0
332.0 355.0
T2D Pre-age 65
Count
3a
43a
46
Expected Count
3.0
43.0 46.0
Total
Count
29
26 375
Expected Count
29.0
26.0 375.0
Each subscript letter denotes a subset of History of Stroke or Brain Hemorrhage categories
whose column proportions do not differ significantly from each other at the .05 level.

32

7.4 ANOVA ANALYSES
Four ANOVA models were calculated. Each of these models used gender and T2D
diagnosis to predict outcomes on continuous outcome variables including the Mini-Mental Status
Exam (MMSE) scores and the Center for Epidemiologic Studies Depression (CESD20) scale
scores. Each model tested sex (M/F) and T2D (yes/no) as independent factors, and the possible
interaction effect of sex x T2D.
The first hypothesis predicted that respondents with a pre-age 65 diagnosis T2D have
lower (worse) Total MMSE Mini-Mental Status Examination scores, indicative of poorer current
cognitive ability, as compared to respondents with no history of T2D. Sex was included as an
additional factor. As shown in Table 12, this model was not significant (F (3,397) = 0.705, p =
0.550, partial eta squared = .005). The individual effects will be reviewed, nonetheless.
When looking at the main effect of gender, there was insufficient evidence to conclude that
gender influenced MMSE scores (F (1,397) = 0.033, p = 0.865. Similarly, regarding the effect of
T2D diagnosis (pre-age 65 vs none), there was not sufficient evidence to conclude that have an
earlier diagnosis of T2D diagnosis increased MMSE score means (F (1, 397) = 1.596, p = 0.207).
Further, the interaction of gender x T2D was not significant suggesting that males and females
did not differ with regard to whether T2D influenced MMSE scores (F (1, 397) = 0.456, p =
0.500). The adjusted R square (-0.002) suggested that almost none of the observed variance was
explained by the model.
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Table 11. ANOVA Descriptive Statistics for Group Comparisons on MMSE Scores
Descriptive Statistics
Dependent Variable: MMSE Score
Age of T2D
Diagnosis (Never
diagnosed OR before
Gender of the Respondent
age 65)
Male
No T2D
T2D Before Age 65
Total
Female
No T2D
T2D Before Age 65
Total
Total
No T2D
T2D Before Age 65
Total

Mean
20.26
22.45
20.44
20.82
21.49
20.91
20.62
21.72
20.75

Std.
Deviation
6.741
3.751
6.570
6.001
6.368
6.043
6.270
5.826
6.224

N
126
11
137
229
35
264
355
46
401

Table 12. ANOVA Results for MMSE Scores by Gender and Age Dependent T2D Status
Tests of Between-Subjects Effects
Dependent Variable: MMSE Score
Type III
Partial
Sum of
Mean
Eta
Noncent. Observed
Source
Squares
df
Square
F
Sig. Squared Parameter Powerb
Corrected
82.074a
3
27.358
.705 .550
.005
2.114
.200
Model
Intercept
54854.463
1 54854.463 1413.051 .000
.781 1413.051
1.000
SEX
1.274
1
1.274
.033 .856
.000
.033
.054
T2D_Status
61.955
1
61.955
1.596 .207
.004
1.596
.243
SEX *
17.714
1
17.714
.456 .500
.001
.456
.103
T2D_Status
Error
15411.487 397
38.820
Total
188118.000 401
Corrected Total 15493.561 400
a. R Squared = .005 (Adjusted R Squared = -.002)
b. Computed using alpha = .05
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Since the first ANOVA was not significant, another two-way ANOVA was conducted to
test whether respondents with T2D diagnosed at any age (Yes/No) have lower (worse) Total
MMSE Mini-Mental Status Examination scores (indicative of poorer current cognitive ability) as
compared to respondents with no history of T2D. The ANOVA model tested gender and T2D
diagnosis status (Yes/No) as independent factors, and also tested the interaction of gender x T2D.
As shown in Table 14, once again, the overall model was not statistically significant (F (3,502) =
2.027, p = 0.109). In this case however, the model trended towards significant (p = 0.109) and
the individual factor effects were considered with caution.
When looking at the main effect of gender, there was insufficient evidence to conclude
that gender influenced MMSE scores (F (1,502) = 0.252, p = 0.616). Regarding the effect of
T2D diagnosis at any age, the result is interpreted with caution, acknowledging that the overall
model was not significant. The MMSE scores of participants with T2D appeared to differ from
those without T2D (F(1,502) = 5.700, p = 0.017). When the mean scores were examined (Table
13) it was seen that the effect was in the direction opposite to the prediction. The mean MMSE
score of respondents with T2D was in fact higher (better), and not lower, than scores seen in
respondents with no T2D. This intriguing result will be considered in Discussion below. The
interaction of gender x T2D was not significant suggesting that males and females did not differ
regarding whether T2D influenced MMSE scores (F (1,502) = 1.898, p = 0.169). The adjusted R
square for the model approached zero (0.006) suggesting that the model explained almost none
of the variance observed.
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Table 13. ANOVA Descriptive Statistics for MMSE Scores by Gender and T2D (yes/no)
Descriptive Statistics
Dependent Variable: MMSE Score
Gender of the
Respondent
T2D Diagnosis
Mean
Male
Yes
22.67
No
20.26
Total
20.93
Female
Yes
21.47
No
20.82
Total
21.02
Total
Yes
21.85
No
20.62
Total
20.99

Std.
Deviation
5.037
6.741
6.395
6.289
6.001
6.090
5.929
6.270
6.190

N
48
126
174
103
229
332
151
355
506

Table 14. ANOVA Results for MMSE Scores by Gender and T2D (yes/no)
Tests of Between-Subjects Effects
Dependent Variable: MMSE Score
Type III
Partial
Sum of
Mean
Eta
Noncent. Observed
Source
Squares
df
Square
F
Sig. Squared Parameter Powerb
Corrected
231.615a
3
77.205
2.027 .109
.012
6.082
.521
Model
Intercept
169485.912
1 169485.912 4450.284 .000
.899 4450.284
1.000
SEX
9.608
1
9.608
.252 .616
.001
.252
.079
T2D
217.092
1
217.092
5.700 .017
.011
5.700
.664
SEX * T2D
72.273
1
72.273
1.898 .169
.004
1.898
.280
Error
19118.314 502
38.084
Total
242244.000 506
Corrected
19349.929 505
Total
a. R Squared = .012 (Adjusted R Squared = .006)
b. Computed using alpha = .05
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ANOVA was also used to test group differences on CES-D 20 scores. This analysis
examined whether participants with an earlier history of T2D as compared to those with no T2D
diagnosis had higher CESD 20 scores (16 points or more = “depression”).
Similar to the above models, this ANOVA tested whether sex, T2D, pre-age 65 vs. no
T2D, and/or the interaction, predicted CESD 20 scores. As shown in Table 16, the overall model
was significant (F (3,397) = 4.553, p = 0.004) suggesting that the full complement of factors
predicted CESD 20 scores, and the individual effects were examined to determine the source of
the significant effects.
Interestingly in this model, while the overall model was significant, none of the
individual effects were significant. Gender did not appear to significantly influence CESD scores
in this model (F (1,397) = 0.586, p = 0.177). Similarly, regarding the influence of T2D diagnosis
before age 65 on CESD20 scores, the effect was not significant (F (1, 397) = 1.507, p = 0.220)
and the interaction was also not significant (F (1,397) = 0.586, p = 0.445). The adjusted R
square for the model was low (0.026) suggesting that the model explained very little amount of
the variance observed.
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Table 15. ANOVA Descriptive Statistics for CESD20 Scores by Gender and Pre-65 T2D
Descriptive Statistics
Dependent Variable: Total CES-D Score
Gender of the
T2D Diagnosed (T2D <
Respondent
65 vs. no T2D)
Mean
Male
No T2D
10.10
T2D Before Age 65
13.00
Total
10.33
Female
No T2D
13.18
T2D Before Age 65
13.86
Total
13.27
Total
No T2D
12.09
T2D Before Age 65
13.65
Total
12.27

Std.
Deviation
6.311
9.000
6.572
8.498
9.930
8.683
7.922
9.625
8.137

N
126
11
137
229
35
264
355
46
401

Table 16. ANOVA Results for CESD20 Scores by Gender, pre-65 T2D, and the Interaction
Tests of Between-Subjects Effects
Dependent Variable: Total CES-D Score
Type III
Partial
Sum of
Mean
Eta
Noncent. Observed
Source
Squares df
Square
F
Sig. Squared Parameter Powerb
Corrected
881.009a
3 293.670 4.553 .004
.033
13.660
.885
Model
Intercept
19073.6
1 19073.63 295.72 .000
.427 295.728
1.000
37
7
8
SEX
118.114
1 118.114 1.831 .177
.005
1.831
.271
T2D_Status
97.172
1
97.172 1.507 .220
.004
1.507
.232
SEX *
37.770
1
37.770
.586 .445
.001
.586
.119
T2D_Status
Error
25605.4 397
64.497
40
Total
86827.0 401
00
Corrected Total 26486.4 400
49
a. R Squared = .033 (Adjusted R Squared = .026)
b. Computed using alpha = .05
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Finally, one additional two-way ANOVA was conducted to compare whether
respondents with diagnosed T2D (Yes/No) have lower (worse) Total CES-D scores as compared
to respondents with no history of T2D. Similar to the above models, this ANOVA tested whether
gender, T2D and/or the interaction, predicted CESD20 scores.
As shown in Table 19 the overall model was significant (F (3,506) = 4.965, p = 0.002)
suggesting that factors provide a better fit than would be provided by a model with no predictive
factors. To understand the possible source of this significant outcome, the individual effects and
interaction were considered. The main effect of gender was significant (F (1,502) = 9.320, p =
0.002). When the mean values were examined (Table 17), females were found to have mean
CESD20 scores approximately 3 points higher than males. Regarding the effect of T2D diagnosis
on CESD20 scores, there was no significant effect (F (1,502) = 1.247, p = 0.265). Also, there
were no statistically significant effect of the interaction (F (1,502) = 0.347, p = 0.556) suggesting
that the effect of T2D diagnosis on CESD20 scores did not differ in males and females. Despite
these findings, it was noted that the adjusted R square for the model was low (0.023) suggesting
that the model explained very little amount of the total variance observed.
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Table 17. ANOVA Descriptive Statistics for CESD20 Scores by Gender and T2D (yes/no)
Descriptive Statistics
Dependent Variable: Total CES-D Score
Gender of the
Respondent
T2D Diagnosis
Mean
Male
Yes
11.54
No
10.10
Total
10.49
Female
Yes
13.63
No
13.18
Total
13.32
Total
Yes
12.97
No
12.09
Total
12.35

Std.
Deviation
6.885
6.311
6.487
9.916
8.498
8.949
9.092
7.922
8.289

N
48
126
174
103
229
332
151
355
506

Table 18. ANOVA Results for CESD20 Scores by Gender, T2D (yes/no) and the Interaction
Tests of Between-Subjects Effects
Dependent Variable: CESD: Total CES-D Score
Type III
Partial
Sum of
Mean
Eta
Noncent. Observed
Source
Squares
df
Square
F
Sig. Squared Parameter Powerb
Corrected
1000.034a
3
333.345
4.965 .002
.029
14.896
.913
Model
Intercept
54790.866
1 54790.866 816.147 .000
.619 816.147
1.000
SEX
625.673
1
625.673
9.320 .002
.018
9.320
.861
T2D/any
83.733
1
83.733
1.247 .265
.002
1.247
.200
SEX *
23.282
1
23.282
.347 .556
.001
.347
.090
T2D/any
Error
33701.051 502
67.134
Total
111875.000 506
Corrected
34701.085 505
Total
a. R Squared = .029 (Adjusted R Squared = .023)
b. Computed using alpha = .05
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CHAPTER 8: DISCUSSION
According to the CDC, in 2018, approximately 1.5 million new cases of T2D were
diagnosed in the United States (National Diabetes Statistics Report, 2020). Among these cases,
people of Hispanic origin (9.7 per 1,000) and non-Hispanic blacks (8.2 per 1,000) had a higher
incidence of T2D as compared to non-Hispanic whites (5.0 per 1,000) (CDC, 2020). While the
overall incidence of T2D decreased between 2008 and 2018, the ethnic disparities persist.
According to the National Diabetes Statistics Report, 2020, there has been an identifiable
increase in the incidence of T2D in youth, ages 10-19, specifically in racial and ethnic minorities,
while rates among non-Hispanic whites are stable. This report also shows evidence provided
bythe SEARCH for Diabetes in Youth study, which showed that from 2002 – 2012 the rate of
new diagnosed cases of T2D increased by 4.8% in youth (NIH, 2017). It is important to further
explore the increased incidence of T2D in younger populations in order to develop studies that
can help prevent/delay and treat T2D and ultimately allow for better health outcomes as age
progresses.
When considering undifferentiated dementia, there seems to have been a decreasing trend
in incidence, while Alzheimer’s alone has steadily increased in the last for decades, according to
a systematic review (Gao et al., 2019). Studies also showed that the decreases in undifferentiated
dementia may be attributed to an increase in both levels of education and improved
cardiovascular control (Alzheimer’s Association, 2021). According to the estimates collected
through the CHAP study and U.S. Census, there were about 910,000 people aged 65 years or
older who developed Alzheimer’s disease/Dementia in the U.S. in 2011 (Alzheimer’s
Association, 2021). From these data, the Alzheimer’s Association estimated that the annual
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number of cases is expected to increase, primarily with the increasing number of people aged 65
and older.
Both T2D and Alzheimer’s Disease/Dementia have serious physiological impacts and
symptoms that are important to discuss. With the increase in the nation’s older population, it is
necessary to understand the negative impacts both chronic diseases carry in regard to a person’s
overall wellbeing. Moreover, the physiological impact and symptoms these diseases exhibit are
primarily afflicting communities of color. Managing T2D is essential in reducing or eliminating
the risk of both cardiovascular and diabetic neuropathy, all of which can lead to serious
complications. Regarding Alzheimer’s disease/Dementia, apart from cognitive decline, death is a
serious complication that is often experienced with this disease. Overall, by addressing the
concerning physiological nature of both diseases, severe health problems may be delayed or
prevented altogether.
8.1 PURPOSE
The purpose of this study was to determine if further designed studies could be warranted
based on the results of this secondary data analysis performed on publicly available data
(HEPESE Wave 8). The specific goal of this study was to examine whether older Mexican
American individuals with a history of T2D were more likely to develop later cognitive
impairment and/or depression without cognitive decline. It was predicted that elderly participants
(mean age at time of Wave 8 interview = 87.87 years) with a history of T2D onset prior to age
65, were more likely to have dementia-related symptoms and/or symptoms of depression, as
compared to elderly participants with no earlier history of T2D. Specifically, respondents with
T2D were predicted to have greater likelihood of diagnosed dementia (yes/no); lower (worse)
Total Mini-Mental Status Examination scores; and higher depression rating scale scores.
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8.2 FINDINGS
The secondary data analysis of HEPESE Wave 8 data revealed different findings than
predicted. Although the overall model for the analysis of MMSE scores using two-way ANOVA
revealed no statistical significance, when direction of possible effects was examined, scores were
in opposite direction as predicted. Participants who had T2D were shown to have higher scores
on MMSE, rather than lower. Since participants who reported a T2D diagnosis had higher scores
on the MMSE, indicative of little to no cognitive impairment, it would be valuable to determine
if treatment of T2D offers a protective factor on brain function.
A meta-analysis conducted by Ye et al. (2016), discovered that insulin sensitizer drugs
(metformin and thiazolidinediones), reduced the incidence of dementia 544,093 participants.
Currently, there is little research on the overall effect of diabetes medications and how they
impact the risk of developing dementia.
When looking at the possible impact of earlier T2D diagnosis on emotional functions,
specifically depression, CES-D scores were considered and analyzed in those with and without
T2D. The overall model in which two-way ANOVA testing was run to test the effect on CES-D
scores were significant, and the effects were attributable to females reporting more depression
than males. These findings may suggest that males with T2D are underreporting their symptoms,
and/or may be suppressing their expression of depression. It is also possible that females are
more subject to depression with a diagnosis of T2D.
According to the ADA, women have depression about twice as much as men in general,
but the incidences increase when a woman has diabetes. Increased depression in women with
diabetes has been attributed to different biological, hormonal, and/or social factors women
experience in their lifetimes (NAMI, 2020). For instance, women undergo many hormonal
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changes (menstruation, pregnancy, miscarriage, postpartum period, pre-menopause, and
menopause), and additional life stressors such as work and caregiving that impact the risk of
developing depression (ADA, 2021). The ADA also suggests that women having higher rates of
depression because of the clinical diagnosis itself (2021). According to the National Institute on
Mental Health, a reason men may not be diagnosed as much as their female counterparts is
because they are less likely to talk about or seek treatment and even recognize their symptoms as
depression (2017).
8.3 FUTURE STUDIES
Future follow up studies are necessary and need to be conducted to help determine if the
treatment of T2D with medication and healthy lifestyle choices (exercise and diet), are
potentially protective for the brain and for cognitive functioning. Additional studies specifically
designed to examine the associations between T2D, and later cognitive functioning and
impairment should be carried out. Future studies would benefit from using more comprehensive
neurocognitive testing batteries rather than relying on a quick screen method such as the MMSE.
For example, for a future study, participants could be split into three identifiable groups
for analysis, consisting of (1) no T2D diagnosis, (2) T2D diagnosis pre-age 65, and (3) T2D
diagnosis post-age 65. In total, each group should have at least an n = 150. They should also be
more than 65 years or older to participate in the study. The following variables should be
collected for all participants in the exploratory research study: (1) Gender (M/F), (2) T2D
diagnosis status (yes/no), (3) Age when diagnosed with T2D -if applicable, (4) taking insulin
(yes/no), (5) taking prescribed medication for T2D (yes/no), and (6) neurocognitive test battery
scores.
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Another possible explanation of the trend that those with T2D had higher MMSE scores,
is that recommended dietary changes may have had protective effects on brain function. To
determine how different dietary behaviors may impact cognitive function in those with T2D,
another type of study design could be considered. For example, the study could include groups
distinguished by the levels of blood sugar identified (high, medium, low – higher having worse
implications), the age of T2D diagnosis (younger have worse implications), BMI, and blood
pressure (high, low, normal) reading. Participants could be assessed using the Healthy Eating
Index (HEI-2015), in which a person’s diet is assessed to determine the overall quality of their
diet and how well they align with the 2015-2020 dietary guidelines for Americans. Higher scores
would be indicative of closely aligning with these dietary guidelines (USDA, 2018).
Additionally, participants could also be tested using a neurocognitive battery, to gauge cognitive
functioning related to dementia. Each group (T2D pre-age 65, T2D post-age 5, and No T2D),
should have a minimum of n = 105. Overall, these factors should be explored to get closer to
understanding if healthy dietary behaviors in people with T2D act as protective factors in
cognitive functioning.
When looking at the outcomes of the CES-D scores regarding those who have T2D, it is
also important, from a research standpoint, to further investigate why the observed effects may
exist. Studies could be conducted to re-test the differences in depression between males and
females with T2D. The overall design of the study compares those with and without a T2D
diagnosis in persons aged 65 years or older. This study could be split into two identifiable groups
for analysis, (1) No T2D diagnosis and (2) T2D diagnosis, with a minimum of n = 300 for each
group. They should also be further split by gender (M/F). For instance, two groups should exist
for each level of T2D diagnosis: Males (n = 150) and females with T2D (n = 150) vs. males (n =
45

150) and females (n = 150) without T2D (N = 600). For all individuals, a CES-D test could be
conducted and scored. Additionally, secondary variables should also be collected to identify
depression in participants. For example, these variables could look at whether the participant has
accessed psychiatric services (yes/no) as well as ever attended therapy (yes/no). Overall, this
exploratory study would aim to determine whether the differences in depression symptoms by
gender are due to male underreporting of depressive symptoms, or because of the different
effects of T2D on males and females.
8.4 LIMITATIONS
Because this was a secondary data analysis, the quality of data collection and how well
responses were monitored could not be known and were out of the researcher’s control. While all
possible subjects were used for these analyses, the sample size became limited among some
subgroups reducing the statistical power for detecting effects. The effect of the limited sample
size was most evident when looking at ANOVA analyses.
8.5 CONCLUSION
Few studies have examined the effects of T2D on later cognitive and emotional
functioning. Given the large numbers of people with T2D in the U.S. today, understanding its
long-term effects on brain systems is very important. In this exploratory study using secondary
data, responses were analyzed from N = 506 elderly males and females between the ages of 82
and 103. Overall, there were few significant findings. At the same time however, an interesting
trend in the data suggested that having earlier T2D may have increased (rather than decreased)
MMSE scores later in life for both males and females. Regarding emotional functioning, only
females appeared to suffer substantially more symptoms of depression. Additional studies are
needed to further examine effects on mental status, and to also determine whether depression
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among females is attributable to the earlier history of T2D or reflects the commonly found
reporting bias for symptoms of depression among males and females.
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